Compare Ginkgo Bioworks Holdings Inc (DNA) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Newmont Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9 (market cap $590.53M), while Newmont Corporation trades at $95.22 (market cap $101.15B). The key difference: Newmont Corporation is far larger — about 171.3× Ginkgo Bioworks Holdings Inc's market cap, and Newmont Corporation pays a 1.1% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | NEM | |
|---|---|---|
Market Cap | $590.53M | $101.15B |
Sector | Health | Basic Materials |
52-Week High | $16.14 | $131.95 |
52-Week Low | $5.48 | $57.35 |
Enterprise Value | $627.78M | $97.90B |
Dividend Yield | — | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Newmont (NEM) trades at $93.10, down 2.3% over the past day amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 12.08, net income margin of 33.87%, and three consecutive quarterly earnings beats. Recent news highlights Wall Street's positive valuation view despite near-term cost pressures. Cash flow trends are robust, with operating cash flow rising to $10.33 billion in 2025.
Outlook remains favorable given analyst consensus of a $140.11 price target and 75% buy ratings. Key risks include higher unit costs impacting 2026 margins and gold price volatility. The stock offers value with solid profitability and growth, though investors should monitor cost management and gold market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
